All News
Can we withdraw treatment in post-menopausal osteoporosis?
d
EurekAlert!
Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.
Read Article
Dual seropositivity and shared epitopes in RA: friends or foes?
Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.
Read Article
3 pain clusters in AxSpA - tres intéressant @RheumNow #EULAR2024 https://t.co/ZgXvsxHlJu
Peter Nash drpnash ( View Tweet)
OP0202 looks at phenotypes of #RAILD in a cluster analysis
🌎Large multinational cohort
2⃣Two key clusters identified
📈Male sex, older age at RA & ILD onset, European ethnicity, smoking and CCP & RF positivity more frequent in cluster 1 vs 2
@RheumNow #EULAR2024 @Juge_P_A
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty
Dr. John Cush RheumNow ( View Tweet)
GOLMePsA RCT early naive PsA
Golimumab or PBO in addition to MTX+IM GCs
No difference wk52
ACR20 GOL 76% PBO 55%
MDA GOL 55% PBO 41%
PBO arm received higher GC dose
No new safety signal
@RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm
Aurelie Najm AurelieRheumo ( View Tweet)
📺 Join @RheumNow, @Yuz6Yusof & I for the Daily Recap over on @YouTube
⏩ https://t.co/D3HZGUdi9t
⏰ TODAY 18:00 CEST
👋 See you there!
#EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
Nationwide epi study of lymphoproliferative disorders in Sjogren's. All pts in France!
4 % prevalence
More in males and those with cryos and MGUS
#EULAR2024
@rheumnow
abst#OP0207 https://t.co/bEaWpTD7x3
Links:
Bella Mehta bella_mehta ( View Tweet)
Severe refractory Sjogrens - not in RCTs but some meds such as CD20 - Obinutuzumab, CART have been reported.
A summary of slides @RheumNow https://t.co/9HQRAj3rzt
Links:
Bella Mehta bella_mehta ( View Tweet)
CD40 and CD40L (CD154) inhibition
CD-40 monoclonal antibody
CD 40 Ligand blockade- Dazodalibep
@RheumNow https://t.co/n9CcrujVwa
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0237 RNA-seq of muscle biopsy in inflammatory myopathy (IIM) showed distinct gene expressions underlying muscle damage between DM, Antisynthetase & PM. Potential targets for future therapeutics @RheumNow @IzukaShinji https://t.co/nf0pp2RhaE
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Current and future treatment in Sjogrens Syndrome @rheumnow #EULAR2024
Many failed trails - likely secondary to non validated outcomes.
3 major domains - sicca, extraglandular manifestations, constitutional https://t.co/cCYX1YCqG2
Links:
Bella Mehta bella_mehta ( View Tweet)
"T and B cells playing tennis" In Sjogren's Syndrome!
Thomas Dorner - #EULAR2024 @rheumnow https://t.co/Lum0A9cY9U
Bella Mehta bella_mehta ( View Tweet)
Isolated ⬆️ serum #IgG4 level:
💎💎💎 (Dr. Stone):
❓How high? >5x ULN ➡️PPV 75%‼️
❓Typical organ(s) involved?
❓Another explanation?
#eular2024
#rheumx
@eular_org
@RheumNow https://t.co/pm6wjvi2Vt
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Different clusters - subpopulations of Sjogrens syndrome may exist and getting patient input is important @RheumNow https://t.co/7v5MYzzotT
Links:
Bella Mehta bella_mehta ( View Tweet)
How to assess treatment in Sjogren's Syndrome
#EULAR2024 @RheumNow
1) define the target population
2) standardize inclusion criteria
3) Restricting ESSDAI domain to 5 domains
4) Correct endpoint choice https://t.co/m7DvZdpuZa
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 POS0223 UK multicentre data showed real-world avacopan use in #vasculitis differed from RCT: it was started later;often combined w other IS; GC tapering varied; 20% had eGFR<15. Compared to historical cohort of GC taper, OR of clinical response in AVA was 3.6 @RheumNow https://t.co/MP3OrRSJ0U
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjogrens Syndrome - bench to bedside session.
#EULAR2024 @RheumNow
Important to concentrate on non infiltrative patients. (to find different / early phenotypes?) https://t.co/ezFkX6CW8l
Links:
Bella Mehta bella_mehta ( View Tweet)
Real world data of safety profiles in SpA and Secukinumab- in all age groups #POS0199 #EULAR2024 @RheumNow https://t.co/q0FFP2SMLl
Bella Mehta bella_mehta ( View Tweet)
Very contradictory study in Axial SpA- no evidence of better drug retention or better treatment response compared to a later start of treatment.
Data of early and very early disease. POs0204 #EULAR2024 @RheumNow https://t.co/6ci6xfyRmq
Bella Mehta bella_mehta ( View Tweet)